132 related articles for article (PubMed ID: 19060543)
1. Epstein-Barr virus, rapamycin, and host immune responses.
Krams SM; Martinez OM
Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder.
Hatton O; Martinez OM; Esquivel CO
Pediatr Transplant; 2012 May; 16(3):220-9. PubMed ID: 22353174
[TBL] [Abstract][Full Text] [Related]
3. The role of mTOR in memory CD8 T-cell differentiation.
Araki K; Youngblood B; Ahmed R
Immunol Rev; 2010 May; 235(1):234-43. PubMed ID: 20536567
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of IRE1alpha/XBP1 axis prevents EBV-driven lymphomagenesis in NSG mice.
Arena A; Romeo MA; Po A; Benedetti R; Gilardini Montani MS; Gonnella R; Santarelli R; Gaeta A; De Smaele E; Cirone M
Microbiol Spectr; 2023 Dec; 11(6):e0263623. PubMed ID: 37882554
[TBL] [Abstract][Full Text] [Related]
5. Tabelecleucel is effective in EBV-positive lymphoproliferative disease.
Romero D
Nat Rev Clin Oncol; 2024 Apr; 21(4):251. PubMed ID: 38374435
[No Abstract] [Full Text] [Related]
6. On the crossroad between tolerance and posttransplant lymphoma.
Nalesnik MA; Starzl TE
Curr Opin Organ Transplant; 1997 Oct; 2(1):30-35. PubMed ID: 21165166
[TBL] [Abstract][Full Text] [Related]
7. Innate immune responses against Epstein Barr virus infection.
Chijioke O; Azzi T; Nadal D; Münz C
J Leukoc Biol; 2013 Dec; 94(6):1185-90. PubMed ID: 23812328
[TBL] [Abstract][Full Text] [Related]
8. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy.
Li F; Song D; Lu Y; Zhu H; Chen Z; He X
J Immunother; 2013 Apr; 36(3):208-14. PubMed ID: 23502768
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional structure of the Epstein-Barr virus capsid.
Germi R; Effantin G; Grossi L; Ruigrok RWH; Morand P; Schoehn G
J Gen Virol; 2012 Aug; 93(Pt 8):1769-1773. PubMed ID: 22592267
[TBL] [Abstract][Full Text] [Related]
10. In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures.
Ni C; Chen Y; Zeng M; Pei R; Du Y; Tang L; Wang M; Hu Y; Zhu H; He M; Wei X; Wang S; Ning X; Wang M; Wang J; Ma L; Chen X; Sun Q; Tang H; Wang Y; Wang X
Cell Res; 2015 Jul; 25(7):785-800. PubMed ID: 25916549
[TBL] [Abstract][Full Text] [Related]
11. Protein localization in disease and therapy.
Hung MC; Link W
J Cell Sci; 2011 Oct; 124(Pt 20):3381-92. PubMed ID: 22010196
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex.
Matsuura H; Kirschner AN; Longnecker R; Jardetzky TS
Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22641-6. PubMed ID: 21149717
[TBL] [Abstract][Full Text] [Related]
13. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease.
Hatton OL; Harris-Arnold A; Schaffert S; Krams SM; Martinez OM
Immunol Res; 2014 May; 58(2-3):268-76. PubMed ID: 24619311
[TBL] [Abstract][Full Text] [Related]
14. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
[TBL] [Abstract][Full Text] [Related]
15. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
Papalexandri A; Gavriilaki E; Vardi A; Kotsiou N; Demosthenous C; Constantinou N; Touloumenidou T; Zerva P; Kika F; Iskas M; Batsis I; Mallouri D; Yannaki E; Anagnostopoulos A; Sakellari I
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003218
[TBL] [Abstract][Full Text] [Related]
16. A quick algorithmic review on management of viral infectious diseases in pediatric solid organ transplant recipients.
Moghadamnia M; Eshaghi H; Alimadadi H; Dashti-Khavidaki S
Front Pediatr; 2023; 11():1252495. PubMed ID: 37732007
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disease after pediatric kidney transplant.
Fulchiero R; Amaral S
Front Pediatr; 2022; 10():1087864. PubMed ID: 36568415
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits hepatitis B virus covalently closed circular DNA transcription by enhancing the ubiquitination of HBx.
Zhang Y; Li L; Cheng ST; Qin YP; He X; Li F; Wu DQ; Ren F; Yu HB; Liu J; Chen J; Ren JH; Zhang ZZ
Front Microbiol; 2022; 13():850087. PubMed ID: 36033851
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature.
Katz-Greenberg G; Ghimire S; Zhan T; Mallari K; Whitaker-Menezes D; Gong J; Uppal G; Martinez-Outschoorn U; Martinez Cantarin MP
Am J Cancer Res; 2021; 11(9):4624-4637. PubMed ID: 34659910
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
